Juergen Hilman,Wolfgang Heil,Ralph Lipp,Renate Heithecker,Michael Huempel,Johannes W. Tack
申请号：
US13900790
公开号：
US20140050794A1
申请日:
2013.05.23
申请国别(地区):
US
年份:
2014
代理人:
摘要：
A pharmaceutical composition comprises, as a first active agent, 6β,7β15β,16β-dimethene-3-oxo-17α-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17α-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of from about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or excipients.In a specific embodiment, the composition consists of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage units comprises the combination of drospirenone and ethinylestradiol. The composition may further comprise 7 or less daily dosage units containing no active agent or containing ethinylestradiol alone.
